Panel | Jotup

Form 8.3 - Zürcher Kantonalbank: Irish Residential Properties REIT PLC

Retrieved on:

Wednesday, April 10, 2024

Disclosure, Part, Panel, Practice of law

See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

Key Points:

See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.
See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.
If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure.
References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

CCRcorp Conferences Returning to In-Person Programming

Retrieved on:

Tuesday, April 9, 2024

Uncertainty, Conference, COVID-19, National Association, Panel

Register today for this fall's Proxy Disclosure & Executive Compensation Conferences in San Francisco, presented by TheCorporateCounsel.net and CompensationStandards.com

Key Points:

Conference attendees will get the practical guidance and expert knowledge they need as rules, regulations and procedures continue to evolve.
The event, hosted in conjunction with the National Association of Stock Plan Professionals (NASPP) Annual Conference, marks CCRcorp's return to in-person programming since the COVID-19 pandemic in 2020.
"Over the past few years, many members of TheCorporateCounsel.net and CompensationStandards.com have told us how much they looked forward to our conferences returning to an in-person format," said John Jenkins, Managing Editor of CCRcorp.
"We've all felt the same way, and we're delighted that we've been able to do that with this year's conferences.

DZS Completes Divestiture of Asia Business

Retrieved on:

Friday, April 5, 2024

DWDM, Automation, DASAN Networks, Letter, Sabre, BABA, Second, Growth, Panel, ANZ, BDO, Research, Sale, Acquisition, Software, Security (finance), Wi-Fi, DNI, DZS, Investment, Annual report, File, CSP, Velocity, Government, Delinquent, Hearing, ROADM

On Jan. 5, 2024, DZS signed a definitive agreement to sell its Asia operations to DNI, for $48 million (including the elimination of $43 million in debt).

Key Points:

On Jan. 5, 2024, DZS signed a definitive agreement to sell its Asia operations to DNI, for $48 million (including the elimination of $43 million in debt).
With the sale of the Asia business, DZS is expected to be better positioned to achieve higher blended margins, and with a higher percentage of its total revenue resulting from recurring and reoccurring licenses related to its software-centric solutions.
DZS believes that service providers are deemphasizing closed, proprietary and high security-risk solutions and are increasingly adopting open, standards-based, software-defined solutions.
The notification letter has no immediate effect on the listing or trading of DZS common stock on the Nasdaq Capital Market.

WiSA Technologies Announces Nasdaq Acceptance of Compliance Plan

Retrieved on:

Tuesday, April 9, 2024

WiSA Technologies, Inc. (Nasdaq: WISA (the “Company”)), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, announced today that it received a decision from the Nasdaq Hearings Panel (the “Panel”) granting its request for continued listing on The Nasdaq Capital Market, subject to the Company demonstrating compliance with certain Nasdaq Listing Rules (the “Nasdaq Rules”), including the achievement of various interim milestones.

Key Points:

WiSA Technologies, Inc. (Nasdaq: WISA (the “Company”)), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, announced today that it received a decision from the Nasdaq Hearings Panel (the “Panel”) granting its request for continued listing on The Nasdaq Capital Market, subject to the Company demonstrating compliance with certain Nasdaq Listing Rules (the “Nasdaq Rules”), including the achievement of various interim milestones.
WiSA Technologies, Inc. (Nasdaq: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems.
WiSA Technologies, Inc. and the WiSA Technologies, Inc. logo are trademarks of WiSA Technologies, Inc.
The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC.

Golden Sun Health Technology Group Limited Announces Receipt of Nasdaq Delisting Determination and Plan to Appeal

Retrieved on:

Monday, March 25, 2024

Letter, Panel, Notice, Form, Security (finance), Calendar, Hearing, Cryptocurrency

According to the Letter, the Company had not regained compliance with the Minimum Bid Requirement as of March 20, 2024 and is not eligible for a second 180-day period.

Key Points:

According to the Letter, the Company had not regained compliance with the Minimum Bid Requirement as of March 20, 2024 and is not eligible for a second 180-day period.
Specifically, the Company does not comply with the initial listing requirement of $5,000,000 minimum stockholders’ equity for The Nasdaq Capital Market, as contemplated for a second 180-day period.
The Company plans to appeal the Determination to the Panel in due course.
A hearing request will stay the suspension of the Company’s securities and the filing of Form 25-NSE pending the Panel’s decision.

Waldencast Regains Compliance with Nasdaq Filing Requirements

Retrieved on:

Monday, March 25, 2024

WALD, Panel, Periodicity, Hearing

WHITE PLAINS, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, announced that on March 21, 2024 the Company received formal notice from the Nasdaq Hearings Panel (the “Panel”) confirming that it has regained compliance with Nasdaq’s filing requirements, as set forth in Nasdaq Listing Rule 5250(c) (the “Periodic Filing Rule”) following the filing of the Company’s financial results for the interim period ended June 30, 2023 with the U.S. Securities and Exchange Commission.

Key Points:

WHITE PLAINS, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, announced that on March 21, 2024 the Company received formal notice from the Nasdaq Hearings Panel (the “Panel”) confirming that it has regained compliance with Nasdaq’s filing requirements, as set forth in Nasdaq Listing Rule 5250(c) (the “Periodic Filing Rule”) following the filing of the Company’s financial results for the interim period ended June 30, 2023 with the U.S. Securities and Exchange Commission.
In line with the applicable Nasdaq Listing Rules in such circumstances, the notice also indicated that Nasdaq had imposed a “Mandatory Panel Monitor” as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the compliance determination (March 21, 2024), pursuant to which in the event the Company fails to timely satisfy the Periodic Filing Rule during the one-year monitor period, the Company will not have the opportunity to provide a compliance plan for the Nasdaq Listing Qualifications Staff’s review; rather, Nasdaq would instead issue a delist determination pursuant to which the Company could request a hearing and stay of the delist determination pending another hearing before the Panel.
Waldencast is proud to have accomplished this significant milestone and looks forward to providing further updates on its fiscal year 2023 performance in connection with the publication of its 2023 20-F.

Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules

Retrieved on:

Monday, March 25, 2024

Venus, Plan, Panel, Hearing, Equity

On May 31, 2023, Nasdaq Listing Qualifications staff (“Nasdaq Staff”) issued the Company a deficiency notice citing that the stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing under Nasdaq Listing Rule 5550(b)(1) (“Minimum Equity Requirement”).

Key Points:

On May 31, 2023, Nasdaq Listing Qualifications staff (“Nasdaq Staff”) issued the Company a deficiency notice citing that the stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing under Nasdaq Listing Rule 5550(b)(1) (“Minimum Equity Requirement”).
On July 17, 2023, the Company submitted to the Nasdaq Staff a plan to regain compliance with the Minimum Equity Requirement (the "Plan").
At the Hearing, the Company presented a comprehensive compliance plan to regain compliance to the Nasdaq Panel and received the Panel Decision regarding the Nasdaq Listing Rules on March 20, 2024.
“We are grateful for the opportunity from Nasdaq to continue to implement our turnaround plan, " said Rajiv De Silva, Chief Executive Officer of Venus Concept.

Investor Webinar

Retrieved on:

Sunday, March 24, 2024

PDT, Panel

In North America – Tuesday, 26 March at 4:15 pm PDT / 7:15 pm EDT

Key Points:

In North America – Tuesday, 26 March at 4:15 pm PDT / 7:15 pm EDT
Zoom Webinar - details to be provided upon registration.
To register your interest for the webinar please click through to the link below:
After registering your interest, you will receive a confirmation email with information about joining the webinar.
Participants will be able to submit questions via the Panel throughout the presentation, given this is a pre-recorded webinar we highly encourage attendees to send through questions via email beforehand to [email protected] .

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Retrieved on:

Wednesday, March 20, 2024

Sepsis, Development, Lyme disease, Growth, Panel, International, Laboratory, Instrument, LDT, ASPR, Journal of Clinical Microbiology, Pharmaceutical industry

LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.

Key Points:

LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.
The Company is currently in discussions with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories nationwide.
Engaged Dr. Robin Robinson as a strategic advisor to aid in commercialization of the T2Biothreat Panel.
A live and recorded webcast of the call will be available on the “Investors” section of the Company’s website at www.t2biosystems.com .

T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates

Retrieved on:

Tuesday, March 19, 2024

International, Eastern Time Zone, Event, Panel

LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time.

Key Points:

LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com , on the Investors page in the Events & Presentations section.
To listen to the conference call, please dial 1-888-506-0062 (U.S./Canada) or 1-973-528-0011 (International), passcode 688651, approximately ten to five minutes prior to the start time.